Nikhil I. Khushalani, MD, discusses the rationale for combining nivolumab with bempegaldesleukin for the treatment of patients with newly diagnosed, unresectable or metastatic melanoma in a randomized, open-label phase III trial.
Nikhil I. Khushalani, MD
Articles by Nikhil I. Khushalani, MD
